These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29315307)

  • 21. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
    Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
    J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.
    Wassner C; Bradley N; Lee Y
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220919231. PubMed ID: 32295453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
    Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reaching High-Risk Patients for HIV Preexposure Prophylaxis.
    Riddell J; Cohn JA
    JAMA; 2016 Jul; 316(2):211-2. PubMed ID: 27404188
    [No Abstract]   [Full Text] [Related]  

  • 25. The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.
    Van Gerwen OT; Yigit I; Crockett KB; Turan B
    AIDS Behav; 2023 May; 27(5):1478-1485. PubMed ID: 36209179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
    Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
    BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.
    Joob B; Wiwanikit V
    J Assoc Physicians India; 2022 Feb; 70(2):11-12. PubMed ID: 35436834
    [No Abstract]   [Full Text] [Related]  

  • 28. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
    Polo R; García-Albéniz X; Terán C; Morales M; Rial-Crestelo D; Garcinuño MA; García Del Toro M; Hita C; Gómez-Sirvent JL; Buzón L; Díaz de Santiago A; Arellano JP; Sanz J; Bachiller P; Alfaro EM; Díaz-Brito V; Masiá M; Hernández-Torres A; Guerra JM; Santos J; Arazo P; Muñoz L; Arribas JR; Martínez de Salazar P; Moreno S; Hernán MA; Del Amo J;
    Clin Microbiol Infect; 2023 Jan; 29(1):85-93. PubMed ID: 35940567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PURLs: On-demand pill protocol protects against HIV.
    Justesen K; Prasad S
    J Fam Pract; 2016 Aug; 65(8):556-8. PubMed ID: 27660840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethics and HIV prevention research: An analysis of the early tenofovir PrEP trial in Nigeria.
    Peterson K; Folayan MO
    Bioethics; 2019 Jan; 33(1):35-42. PubMed ID: 30198594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High pre-exposure prophylaxis awareness and willingness to pay for pre-exposure prophylaxis among young adults in Western Kenya: results from a population-based survey.
    Begnel ER; Escudero J; Mugambi M; Mugwanya K; Kinuthia J; Beima-Sofie K; Dettinger JC; Baeten JM; John-Stewart G; Pintye J
    Int J STD AIDS; 2020 Apr; 31(5):454-459. PubMed ID: 32208816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials.
    Haire B
    J Bioeth Inq; 2015 Jun; 12(2):239-49. PubMed ID: 25038934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
    Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
    Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highlights of HIVR4P // Virtual.
    Harris P; Henderson R
    Lancet HIV; 2021 Mar; 8(3):129. PubMed ID: 33662260
    [No Abstract]   [Full Text] [Related]  

  • 39. Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States.
    McManus KA; Powers S; Killelea A; Tello-Trillo S; Rogawski McQuade E
    JAMA Netw Open; 2020 Jun; 3(6):e207445. PubMed ID: 32492164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
    Quah SP; McIntyre M; Wood A; Mc Mullan K; Rafferty P
    HIV Med; 2021 Feb; 22(2):e5-e6. PubMed ID: 33063431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.